Aptamers Global Market Report 2024

The global aptamers market has grown exponentially in recent years. It will grow from $2.16 billion in 2023 to $2.68 billion in 2024 at a compound annual growth rate (CAGR) of 23.8%. The growth observed in the historical period can be attributed to various factors, including the demand for high-specificity binders, recognition of therapeutic potential, an increase in personalized medicine approaches, exploration of potential applications in various therapeutic areas, the emergence of aptamers as alternatives to antibodies, and the utilization of aptamers in diagnostic point-of-care (POC) devices. These elements collectively played a significant role in shaping the growth trajectory during the historic period.

The global aptamers market is expected to see exponential growth in the next few years. It will grow to $6.42 billion in 2028 at a compound annual growth rate (CAGR) of 24.5%. The anticipated growth in the forecast period can be attributed to several factors, including increasing investments in life sciences, expansion in drug development activities, growth in cancer research initiatives, the demand for rapid detection in emergency settings, advancements in aptamer selection techniques, and regulatory support. Major trends expected in the forecast period include advancements in SELEX (Systematic Evolution of Ligands by Exponential Enrichment) technology, increasing applications of aptamers in diagnostics, continued investments in aptamer research, technological integration with nanotechnology, and initiatives focused on awareness and education in the field of aptamers. These trends are poised to significantly impact and shape the landscape of aptamer applications in the coming years.

The anticipated surge in chronic respiratory diseases stands as a driving force behind the projected growth of the aptamers market. Chronic respiratory ailments involve the narrowing and swelling of airways, often accompanied by excessive mucus production, resulting in breathing difficulties, coughing, shortness of breath, and wheezing during exhalation. Aptamers play a pivotal role in identifying the respiratory syncytial virus (RSV), aiding in early disease detection and facilitating treatment. For instance, as of May 2021, projections shared by the Asthma and Allergy Foundation of America indicated that the number of Americans afflicted with asthma would exceed 25 million. Consequently, the escalating prevalence of chronic respiratory diseases emerges as a prime catalyst propelling the aptamers market's growth.

The escalating emphasis on personalized medicine is poised to drive the trajectory of the aptamers market. Personalized medicine entails tailored medical interventions aligning with individual patient characteristics, encompassing factors like genetics, lifestyle, and environment to enhance the efficacy and precision of healthcare delivery. Aptamers in the realm of Personalized Medicine function as customizable molecular tools for targeted diagnostics and therapies, exhibiting precise binding capabilities to specific molecules within individual patients. Notably, in 2021, as per The Personalized Medicine Coalition, the FDA's CDER approved 50 new molecular entities (NMEs), with 17 (35%) classified as personalized medicines by the Coalition. This surge in approvals for personalized medicines underscores a significant driver propelling the aptamers market forward.

Technological innovations stand out as a pivotal trend gaining momentum within the aptamers market. Key industry players are introducing novel technologies, exemplified by the creation of artificial DNA aptamers, leveraging adaptable and seamless technology to fortify their market positions. For instance, in May 2021, NEC Corporation, a multinational information technology and electronics corporation based in Japan, engineered artificial DNA aptamers with the capacity to bind to the novel COVID-19 (SARS-CoV-2). Utilizing adaptable and seamless technology, these aptamers can target the virus by identifying the three-dimensional structure of the receptor-binding domain (RBD), establishing a robust bond to immobilize the virus and prevent infection.

Prominent players within the aptamers market are spearheading the launch of innovative reagents like Optimer-Fc to tackle challenges prevalent in the immunohistochemistry (IHC) sector. Optimer-Fc represents a groundbreaking reagent designed specifically for automating immunohistochemistry workflows. For instance, in March 2023, UK-based biotech company Aptamer Group plc introduced Optimer-Fc, aimed at revolutionizing automated immunohistochemistry workflows, thereby effectively addressing challenges inherent in the IHC market. The company strategically collaborates with leading IHC firms, conducts meticulous validation of Optimer-Fc's performance, and orchestrates trials in partnership with top-tier pharmaceutical entities. Serving as an alternative to antibodies, Optimer-Fc seamlessly integrates Optimer binders into existing workflows, offering heightened precision and selectivity for disease biomarkers within IHC applications. This innovation assumes significance particularly amid patent expirations for IHC antibodies, presenting a patentable solution to meet evolving market needs.

In a significant development during May 2022, Epicore Biosystems, a US-based digital health and wearable solutions company, executed the acquisition of Eccrine Systems, incorporating its advanced aptamer-based sweat sensing technology into Epicore's array of wearable microfluidic solutions. The acquisition encompasses Eccrine Systems, renowned for its wearable sensor technology and electrochemical aptamer-based technology, enabling the quantification of selected biomarkers within sweat samples. This strategic move bolsters Epicore's sensor technology portfolio, enhancing its capabilities in developing wearable solutions and amplifying its proficiency in leveraging aptamer-based technologies for monitoring targeted biomarkers.

Major companies operating in the aptamers market report are Aptamer Group Limited, SomaLogic Inc., Aptamer Sciences Inc., Aptagen LLC, NeoVentures Biotechnology Inc., Aptus Biotech, Base Pair Biotechnologies Inc., AMS Biotechnology Ltd., Vivonics Inc., TriLink Biotechnologies LLC, Noxxon Pharma SE, AM Biotechnologies LLC, Raptamer Discovery Group, Kaneka Corporation, Novaptech Inc., Maravai Lifesciences Inc., Bio-Techne Corporation, Creative Biolabs Inc., IBA Lifesciences GmbH, Aptabharat Innovations Pvt. Ltd., Profacgen Biotech Inc., Medi GmbH & Co. KG, Pure Biologics Sp. z o.o., Oak BioSciences Inc., Ophthotech Corporation, Novartis AG, NeoNeuro SAS, CAGE Bio Inc., TAGCyx Biotechnologies Inc., AstraZeneca plc, GlyTech Inc., GC Biopharma Corp., Achiko AG, Agilent Technologies Inc., IVERIC bio Inc.

North America was the largest region in the aptamers market in 2023. The regions covered in the aptamers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the aptamers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

There are various types of aptamers, including DNA aptamers, XNA aptamers, and RNA aptamers. DNA aptamers are specific deoxyribonucleic acid (DNA) oligonucleotides capable of binding with high affinity and specificity to target antigens such as peptides, small molecules, cells, proteins, and tissues. They find applications in the design of drug delivery systems. Technologies like SELEX (Systematic Evolution of Ligands by Exponential Enrichment), X-Aptamer, and MARAS (Mirror-Image Aptamer Reverse Selection) techniques are utilized in therapeutic development, research and development, diagnostics, and other applications. Various end users, including pharmaceutical and biotechnology companies, academic and government research institutes, and diagnostic laboratories, employ aptamers for their diverse applications.

This report provides aptamers market statistics, including aptamers industry global market size, regional shares, competitors with an aptamers market share, detailed aptamers market segments, market trends, and opportunities, and any further data you may need to thrive in the aptamers industry. This aptamers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The aptamers market includes revenues earned by entities by providing RNA profiling and detecting cells, viruses, sugars, and antibodies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.